192214-05-4

Basic information

• Product Name: (R)-1-CBZ-3-HYDROXYMETHYLPYRROLIDINE
• Synonyms: (R)-1-CBZ-3-HYDROXYMETHYLPYRROLIDINE;(R)-1-CBZ-BETA-PROLINOL;R-1-Cbz-3-(Hydroxymethyl)piperidine;(R)-benzyl 3-(hydroxyMethyl)pyrrolidine-1-carboxylate;(R)-1-Cbz-3-(hydroxyMethy...;(3R)-3-(Hydroxymethyl)-1-pyrrolidinecarboxylic acid phenylmethyl ester;(R)-3-(Hydroxymethyl)-1-pyrrolidinecarboxylic acid phenylmethyl ester;benzyl (3r)-3-(hydroxymethyl)pyrrolidine-1-carboxylate
• CAS NO: 192214-05-4
• Molecular Formula: C₁₃H₁₇NO₃
• Molecular Weight: 235.28
• Product Categories: pharmacetical
• Mol File: 192214-05-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 381.969 °C at 760 mmHg
• Flash Point: 184.809 °C
• Appearance: /
• Density: 1.196 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-1-CBZ-3-HYDROXYMETHYLPYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-CBZ-3-HYDROXYMETHYLPYRROLIDINE(192214-05-4)
• EPA Substance Registry System: (R)-1-CBZ-3-HYDROXYMETHYLPYRROLIDINE(192214-05-4)

Safety Data

• Hazardous Substances Data: 192214-05-4(Hazardous Substances Data)

Usage

General Description

(R)-1-CBZ-3-HYDROXYMETHYLPYRROLIDINE is a chemical compound that is used in the synthesis of pharmaceuticals, particularly as a chiral intermediate in the production of drugs. It is a pyrrolidine derivative that contains a hydroxymethyl group and a carboxybenzyl (CBZ) protecting group. (R)-1-CBZ-3-HYDROXYMETHYLPYRROLIDINE has potential applications in the development of new drugs and can be used in the creation of various pharmaceutical products. Its unique structure and properties make it valuable in the field of medicinal chemistry and drug discovery.

InChI:InChI=1/C13H17NO3/c15-9-12-6-7-14(8-12)13(16)17-10-11-4-2-1-3-5-11/h1-5,12,15H,6-10H2/t12-/m1/s1

Upstream product

• 501-53-1 benzyl chloroformate 
• 99735-47-4 (3R)-1-[(R)-1-phenylethyl]-3-(hydroxymethyl)pyrrolidine 
• 192214-03-2 (R)-1-Benzyl-4-benzyloxymethyl-pyrrolidin-2-one 
• 192214-02-1 β-azidomethyl γ-butyrolactone 
• 172796-28-0 (R)-4-((benzyloxy)methyl)dihydrofuran-2(3H)-one 
• 85701-08-2 (R)-4-(hydroxymethyl)dihydrofuran-2(3H)-one 
• 5082-74-6 (R)-(+)-3-(hydroxymethyl)pyrrolidine 
• 192214-04-3 (R)-1-Benzyl-3-benzyloxymethyl-pyrrolidine 

Downstream Products

• 1217655-90-7 (R)-methyl-1-benzyloxycarbonyl-pyrrolidine-3-carboxylate 
• 441717-40-4 (R)-methyl-1-tert-butoxycarbonyl-pyrrolidine-3-carboxylate 
• 1436862-03-1 trans-3-[N'-(6-benzyloxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(R)-pyrrolidin-1-carboxylic acid tert-butyl ester 
• 405090-09-7 benzyl (R)-3-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate 
• 1212062-74-2 benzyl (3R)-3-formylpyrrolidine-1-carboxylate 
• 192214-06-5 (R)-1-((benzyloxy)-carbonyl)pyrrolidine-3-carboxylic acid 
• 648418-12-6 (R)-3-(4-Benzyloxycarbonylamino-2-fluoro-phenoxymethyl)-pyrrolidine-1-carboxylic acid benzyl ester 
• 790703-05-8 N-{(S)-3-[3-Fluoro-4-((R)-1-pyrrolidin-3-ylmethoxy)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide 

Relevant articles and documents

AZOLE-SUBSTITUTED PYRIDINE COMPOUND

The present invention provides a compound represented by formula [I'| shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme, wherein the structure represented by formula [III] shown below represents any of the structures represented by formula group [IV] shown below, wherein R1 represents a hydrogen atom, a fluorine atom, methyl, etc.; R2, R3, and R4 each independently represent a hydrogen atom, a fluorine atom, or methyl; W represents a single bond, C1-3alkanediyl, or the formula -O-CH2CH2-; and ring A represents (a) substituted C4-6cycloalkyl, (b) substituted 4- to 6-membered saturated nitrogen-containing heterocyclyl, (c) substituted phenyl, (d) substituted pyridyl, (e) substituted 2,3-dihydrobenzofuran, (f) 4- to 6-membered saturated oxygen-containing heterocyclyl, etc.

A PROCESS FOR PREPARATION OF (2S, 5R)-7-OXO-6-SULPHOOXY-2-[((3R)-PYRROLIDINE-3-CARBONYL)-HYDRAZINO CARBONYL]-1,6-DIAZA-BICYCLO[3.2.1]OCTANE

A process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2- [((3R)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza- bicyclo[3.2.1]octane is disclosed comprising reacting a compound of Formula (II) with a compound of Formula (III) to obtain a compound

Ligands for monoamine receptors and transporters, and methods of use thereof

One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.